Aqualung Therapeutics Corp., An Immunotherapeutics Biotech Company, Closes A $2.5M Convertible Note Raise With A Committed Series A Lead Investor

Aqualung Therapeutics, an early-stage immunotherapeutics company with an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, has closed a $2.5M convertible note fundraise led by a $1.5M investment from JSR Life Sciences, LLC.